



11w

PATENT  
Attorney Docket No. 056291-5283

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: **Robert Hugh BRADBURY et al.** )  
 )  
Application No.: 10/578,663 ) Group Art Unit: *Unassigned*  
 )  
Filed: May 9, 2006 ) Examiner: *Unassigned*  
 )  
For: **QUINAZOLINE DERIVATIVES** ) Date: August 18, 2006

Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Window, Mail Stop Amendment  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Sir:

**INFORMATION DISCLOSURE STATEMENT**

**UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants petition the Examiner to consider this Information Disclosure Statement and documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Information Disclosure Statement.

With the exception of U.S. Patents, copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If it should be determined that the listed documents constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R.

§1.136(a)(3).

Respectfully Submitted,  
Morgan Lewis & Bockius LLP



By: \_\_\_\_\_

Donald J. Bird  
Registration No. 25,323  
Tel. No.: (202) 739-5320  
Fax No.: (202) 739-3001

Date: August 18, 2006  
Morgan Lewis & Bockius LLP  
Customer No. 09629  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
Tel. No.: 202-739-3000

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

AUG 18 2006

PTO Form 1449

August 18, 2006

Attorney Docket No.

056291-5283

Application No.

10/578,663

Applicants: Robert Hugh BRADBURY *et al.*

Filing Date: May 9, 2006

Group Art Unit: *Unassigned*

## U.S. PATENT DOCUMENTS

Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date
1.	US 4,322,420	March 30, 1982	Kobayashi et al.	514	266.4	September 11, 1979
2.	US 4,640,920	February 3, 1987	Boyle et al.	514	248	June 13, 1985
3.	US 5,405,843	April 11, 1995	Fukazawa et al.	514	183	September 9, 1993
4.	US 5,721,237	February 24, 1998	Myers et al.	514	266.1	June 6, 1995
5.	US 5,747,498	May 5, 1998	Schnur et al.	514	266.4	May 28, 1996
6.	US 5,929,080	July 27, 1999	Frost	514	266.4	April 21, 1998
7.	US 5,962,458	October 5, 1999	Lohmann et al.	514	266.21	December 17, 1996
8.	US 6,004,967	December 21, 1999	McMahon et al.	514	266.4	September 11, 1997
9.	US 6,046,206	April 4, 2000	Pamukcu et al.	514	266.21	April 30, 1997
10.	US 6,117,433	September 12, 2000	Edens et al.	424	400	April 28, 1998
11.	US 6,313,130	November 6, 2001	Uckun et al.	514	266.24	July 28, 2000
12.	US 6,326,373	December 4, 2001	Uckun et al.	514	266.1	October 16, 2000
13.	US 6,384,223	May 7, 2002	Gletsos	544	293	May 4, 2000

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

## FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Sub-Class	Translation
14.	EP 0 326 330	July 24, 2002	EPA			
15.	EP 0 520 722	December 27, 1996	EPA			
16.	EP 0 566 226	November 8, 1995	EPA			
17.	EP 0 602 851	October 9, 1996	EPA			
18.	EP 0 787 722	August 6, 1997	EPA			
19.	EP 0 837 063	April 22, 1998	EPA			
20.	GB 2,295,387	May 29, 1996	United Kingdom			
21.	JP-08-003144	January 17, 1996	Japan			Abstract
22.	JP-11-189586	July 13, 1999	Japan			Abstract
23.	WO 92/20642	November 26, 1992	WIPO			
24.	WO 93/08170	April 29, 1993	WIPO			
25.	WO 93/17682	September 16, 1993	WIPO			
26.	WO 95/15758	June 15, 1995	WIPO			
27.	WO 96/09294	March 28, 1996	WIPO			
28.	WO 96/15118	May 23, 1996	WIPO			
29.	WO 96/16960	June 6, 1996	WIPO			
30.	WO 96/30347	October 3, 1996	WIPO			
31.	WO 96/33978	October 31, 1996	WIPO			
32.	WO 96/33978	October 31, 1996	WIPO			
33.	WO 96/33978	October 31, 1996	WIPO			
34.	WO 96/33978	October 31, 1996	WIPO			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner	/Tamthom Truong/	Date Considered	09/05/2008
----------	------------------	-----------------	------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				Attorney Docket No. 056291-5283		Application No. 10/578,663	
				Applicants: Robert Hugh BRADBURY <i>et al.</i>			
PTO Form 1449 August 18, 2006				Filing Date: May 9, 2006		Group Art Unit: <i>Unassigned</i>	

U.S. PATENT DOCUMENTS							
Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date	
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./							

FOREIGN PATENT DOCUMENTS							
	Document No.	Date	Country	Class	Sub-Class	Translation	
	35. WO 96/33981	October 31, 1996	WIPO				
	36. WO 96/39145	December 12, 1996	WIPO				
	37. WO 97/03069	January 30, 1997	WIPO				
	38. WO 97/11692	April 3, 1997	WIPO				
	39. WO 97/13771	April 17, 1997	WIPO				
	40. WO 97/22596	June 26, 1997	WIPO				
	41. WO 97/30034	August 21, 1997	WIPO				
	42. WO 97/30035	August 21, 1997	WIPO				
	43. WO 97/30044	August 21, 1997	WIPO				
	44. WO 97/38983	October 23, 1997	WIPO				
	45. WO 97/38994	October 23, 1997	WIPO				
	46. WO 98/02434	January 22, 1998	WIPO				
	47. WO 98/02437	January 22, 1998	WIPO				
	48. WO 98/02438	January 22, 1998	WIPO				
	49. WO 98/13354	April 2, 1998	WIPO				
	50. WO 98/38984	September 11, 1998	WIPO				
	51. WO 98/50038	November 12, 1998	WIPO				
	52. WO 98/50370	November 12, 1998	WIPO				
	53. WO 99/09016	February 25, 1999	WIPO				
	54. WO 99/24037	May 20, 1999	WIPO				
	55. WO 99/35132	July 15, 1999	WIPO				
	56. WO 99/35146	July 15, 1999	WIPO				
	57. WO 99/61428	December 2, 1999	WIPO				
	58. WO 00/00202	January 6, 2000	WIPO				
	59. WO 00/06555	February 10, 2000	WIPO				
	60. WO 00/10981	March 2, 2000	WIPO				
	61. WO 00/20402	April 13, 2000	WIPO				
	62. WO 00/44728	August 3, 2000	WIPO				
	63. WO 00/47212	August 17, 2000	WIPO				
	64. WO 00/51587	September 8, 2000	WIPO				
	65. WO 00/51991	September 8, 2000	WIPO				
	66. WO 00/55141	September 21, 2000	WIPO				
	67. WO 00/73260	December 7, 2000	WIPO				
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)			

Examiner: /Tamthom Truong/	Date Considered: 09/05/2008
----------------------------	-----------------------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				Attorney Docket No. 056291-5283		Application No. 10/578,663	
PTO Form 1449 August 18, 2006				Applicants: Robert Hugh BRADBURY <i>et al.</i>		Filing Date: May 9, 2006	
Group Art Unit: <i>Unassigned</i>							

U.S. PATENT DOCUMENTS							
Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date	
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./							

FOREIGN PATENT DOCUMENTS							
	Document No.	Date	Country	Class	Sub-Class	Translation	
68.	WO 01/12227	February 22, 2001	WIPO				
69.	WO 01/21594	March 29, 2001	WIPO				
70.	WO 01/21595	March 29, 2001	WIPO				
71.	WO 01/32632	May 10, 2001	WIPO				
72.	WO 01/45641	June 28, 2001	WIPO				
73.	WO 01/77085	October 18, 2001	WIPO				
74.	WO 01/94341	December 13, 2001	WIPO				
75.	WO 01/98277	December 27, 2001	WIPO				
76.	WO 02/18372	March 7, 2002	WIPO				Abstract
77.	WO 02/41882	May 30, 2002	WIPO				
78.	WO 03/082290	October 9, 2003	WIPO				
79.	WO 03/082831	October 9, 2003	WIPO				
80.	WO 2004/096226	November 11, 2004	WIPO				
81.	WO 2005/026151	March 24, 2005	WIPO				
82.	WO 2005/026152	March 24, 2005	WIPO				
83.	WO 2005/028469	March 31, 2005	WIPO				
84.	WO 2005/028470	March 31, 2005	WIPO				
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)	
85.	Ballard et al. "5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase" <i>Bioorg Med Chem Lett.</i> 15(19):4226-4229 (2005) .
86.	Ballard et al. "Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket" <i>Bioorg Med Chem Lett.</i> 16(6):1633-1637 (2006) .
87.	Barker et al. "Studies leading to the identification of ZD1839 (Iressa <sup>TM</sup> ): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer" <i>Bioorganic and Medicinal Chemistry Letters</i> 11(14):1911-1914 (2001) .
88.	Bridges et al. "Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor" <i>J. Med. Chem.</i> 39(1):267-276 (1996) .
89.	Denny et al. "Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site for the epidermal growth factor receptor in vitro" <i>Clinical and Experimental Pharmacology and Physiology</i> 23:424-427 (1996) .
90.	Hennequin et al. "Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors" <i>J. Med. Chem.</i> 45 (6):1300 -1312 (2002) .
90.	Rewcastle et al. "Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor" <i>J. Med. Chem.</i> 38:3482-3487 (1995) .

Examiner	Date Considered	
/Tamthom Truong/	09/05/2008	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.